Odysight.ai Inc 10-Q for FY2022 Q2
Odysight.ai Inc. (ODYS)
About this 10-Q
Odysight.ai Inc filed this 10-Q on August 11, 2022, covering the quarter ended June 30, 2022 (FY2022 Q2).
Headline figures
Quarter ended June 30, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $370K
- up 35.0% from $274K a year earlier
- Net loss
- $2.77M
- compared with a net loss of $2.09M a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission
File No.
| (Exact name of registrant as specified in its charter) |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
| (Registrant’s telephone number, including area code) |
| (Former name, former address and former fiscal year, if changed since last report) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| N/A | N/A | N/A |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☐ | Large accelerated filer | ☐ | Accelerated filer |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
As of August 11, 2022, the registrant had shares of common stock, par value $0.001, of the registrant issued and outstanding.
As used in this Quarterly Report and unless otherwise indicated, the terms “ScoutCam,” “we,” “us,” “our,” or “our Company” refer to ScoutCam Inc. Unless otherwise specified, all dollar amounts are expressed in United States dollars.
SCOUTCAM INC.
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS
| Page | ||
| Cautionary Note Regarding Forward-Looking Statements | 3 | |
| PART 1-FINANCIAL INFORMATION | ||
| Item 1. | Consolidated Financial Statements (unaudited) | 4 |
| Consolidated Balance Sheets | 5 | |
| Consolidated Statements of Comprehensive Loss | 7 | |
| Statements of Stockholders’ Equity | 8 | |
| Consolidated Statements of Cash Flows | 10 | |
| Notes to Consolidated Financial Statements | 12 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 20 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 26 |
| Item 4. | Control and Procedures | 26 |
| PART II-OTHER INFORMATION | ||
| Item 1A. | Risk Factors | 27 |
| Item 6. | Exhibits | 27 |
| SIGNATURES | 28 | |
| - 2 - |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events.
Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2021 (filed on March 30, 2022) entitled “Risk Factors” as well as in our other public filings.
In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.
| - 3 - |
Item 1. Financial Statements
ScoutCam INC.
INTERIM FINANCIAL STATEMENTS
AS OF JUNE 30, 2022
CONSOLIDATED SCOUTCAM INC.
| Page | |
| Interim Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands | |
| Interim Condensed Consolidated Balance Sheets (unaudited) | 5 |
| Interim Condensed Consolidated Statements of Operations (unaudited) | 7 |
| Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited) | 8 |
| Interim Condensed Consolidated Statements of Cash Flows (unaudited) | 10 |
| Notes to the Interim Condensed Consolidated Financial Statements | 12 |
| - 4 - |
SCOUTCAM INC.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Unaudited | Audited | |||||||
| USD in thousands | ||||||||
| Assets | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | ||||||||
| Short terms deposits | ||||||||
| Accounts receivable | ||||||||
| Inventory | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| NON-CURRENT ASSETS: | ||||||||
| Contract fulfillment assets | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use assets | ||||||||
| Severance pay asset | ||||||||
| Total non current assets | ||||||||
| TOTAL ASSETS | ||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| - 5 - |
SCOUTCAM INC.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Unaudited | Audited | |||||||
| USD in thousands | ||||||||
| Liabilities and shareholders’ equity | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payables | ||||||||
| Contract liabilities - short term | ||||||||
| Operating lease liabilities - short term | ||||||||
| Accrued compensation expenses | ||||||||
| Related parties | ||||||||
| Other accrued expenses | ||||||||
| Total current liabilities | ||||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Contract liabilities - long term | ||||||||
| Operating lease liabilities - long term | ||||||||
| Liability for severance pay | ||||||||
| Total non current liabilities | ||||||||
| TOTAL LIABILITIES | ||||||||
| SHAREHOLDERS’ EQUITY: | ||||||||
| Common stock, $ par value; shares authorized as of June 30, 2022 and December 31, 2021, shares issued and outstanding as of June 30, 2022 and December 31, 2021 | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY | ||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| - 6 - |
SCOUTCAM INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Six months ended | Three months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands (except per share data) | ||||||||||||||||
| Revenues | ||||||||||||||||
| Cost of revenues | ||||||||||||||||
| Gross Loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Research and development expenses | ||||||||||||||||
| Sales and marketing expenses | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income | ||||||||||||||||
| Financing income (expenses), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Net Loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Net loss per ordinary share (basic and diluted, USD) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Weighted average ordinary shares (basic and diluted, in thousands) | ||||||||||||||||
| - 7 - |
SCOUTCAM INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
Six Months Ended June 30, 2022 (Unaudited)
| Number | Amount | capital | deficit | Equity | ||||||||||||||||
| Ordinary shares | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | deficit | Equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance at January 1, 2022 | ( | ) | ||||||||||||||||||
| Stock based compensation | - | |||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balance at June 30, 2022 | ( | ) | ||||||||||||||||||
Three Months Ended June 30, 2022 (Unaudited)
| Ordinary shares | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | deficit | Equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance at April 1, 2022 | ( | ) | ||||||||||||||||||
| Stock based compensation | - | |||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balance at June 30, 2022 | ( | ) | ||||||||||||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| - 8 - |
Six Months Ended June 30, 2021 (Unaudited)
| Ordinary shares | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | deficit | equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance at January 1, 2021 | ( | ) | ||||||||||||||||||
| Issuance of shares and warrants | ||||||||||||||||||||
| Stock based compensation | - | |||||||||||||||||||
| Exercise of warrants | ||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balance at June 30, 2021 | ( | ) | ||||||||||||||||||
Three Months Ended June 30, 2021 (Unaudited)
| Ordinary shares | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | deficit | Equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance at April 1, 2021 | ( | ) | ||||||||||||||||||
| Exercise of warrants | * | |||||||||||||||||||
| Stock based compensation | - | |||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balance at June 30, 2021 | ( | ) | ||||||||||||||||||
| * |
| - 9 - |
SCOUTCAM INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Six months ended | Three months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Adjustments to reconcile net loss to net cash used in operations: | ||||||||||||||||
| Depreciation | ||||||||||||||||
| Changes in severance pay asset, net | ( | ) | ( | ) | ||||||||||||
| Share based compensation | ||||||||||||||||
| Profit from exchange differences from operating lease liability | ( | ) | ( | ) | ||||||||||||
| Loss (Profit) from exchange differences on cash and cash equivalents | ( | ) | ( | ) | ||||||||||||
| Interest income in respect of deposits | ( | ) | ( | ) | ||||||||||||
| CHANGES IN OPERATING ASSET AND LIABILITY ITEMS: | ||||||||||||||||
| Increase in accounts receivable | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Decrease (increase) in inventory | ( | ) | ( | ) | ||||||||||||
| Decrease in operating lease liability | ( | ) | ( | ) | ||||||||||||
| Decrease in ROU asset | ||||||||||||||||
| Increase (decrease) in related parties | ( | ) | ||||||||||||||
| Decrease (increase) in other current assets | ( | ) | ( | ) | ||||||||||||
| Increase (decrease) in account payables | ( | ) | ||||||||||||||
| Decrease (increase) in contract fulfillment assets | ( | ) | ( | ) | ||||||||||||
| Increase (decrease) in contract liabilities | ( | ) | ( | ) | ||||||||||||
| Increase in accrued compensation expenses | ||||||||||||||||
| Increase (decrease) in other accrued expenses | ( | ) | ( | ) | ||||||||||||
| Net cash flows used in operating activities | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||||||
| Purchase of property and equipment | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Withdrawal of short terms deposits | ||||||||||||||||
| Investment in short term deposits | ( | ) | ( | ) | ||||||||||||
| Net cash flows provided by (used in) investing activities | ( | ) | ( | ) | ||||||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||||||
| Proceeds from exercise of warrants | ||||||||||||||||
| Proceeds from issuance of shares and warrants | ||||||||||||||||
| Net cash flows provided by financing activities | ||||||||||||||||
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ( | ) | ( | ) | ||||||||||||
| PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS | ( | ) | ( | ) | ||||||||||||
| BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | ||||||||||||||||
| BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | ||||||||||||||||
| - 10 - |
Non cash activities -
| Six months ended | Three months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| Issuance expenses | ||||||||||||||||
| Right-of-use assets obtained in exchange for operating lease liabilities | ||||||||||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| - 11 - |
SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – GENERAL:
| a. | ScoutCam Inc. (the “Company”), formerly known as Intellisense Solutions Inc., (“Intellisense”), was incorporated under the laws of the State of Nevada on March 22, 2013. Prior to the closing of the Exchange Agreement (as defined below), the Company was a non-operating “shell company”.
The Company’s wholly owned subsidiary, ScoutCam Ltd. (“ScoutCam”), was formed in the State of Israel on January 3, 2019, as a wholly-owned subsidiary of Medigus Ltd. (“Medigus”), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019.
In December 2019, Medigus and ScoutCam consummated an asset transfer agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to ScoutCam.
On December 30, 2019, Intellisense and Medigus consummated a securities exchange agreement (the “Exchange Agreement”), pursuant to which Medigus delivered 100% of its holdings in ScoutCam to Intellisense in exchange for shares of Intellisense’s common stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the consummation of the Exchange Agreement.
As of June 30, 2022, Medigus beneficially owned 27.01% of the Company’s outstanding common stock.
The Company, through ScoutCam, provides image-based platforms. Through the use of its proprietary visualization technology, ScoutCam offers solutions across predictive maintenance and condition-based monitoring markets, in sectors such as energy, automotive and aviation. ScoutCam’s solutions are based on small and highly resilient cameras, specialized AI analysis and supplementary technologies. |
| - 12 - |
SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – GENERAL (continued):
| b. | On
August 9, 2021, the Company amended its Articles of Incorporation to effect a | |
| c. | Since
incorporation of ScoutCam and through June 30, 2022, the Company accumulated a deficit of approximately $ | |
| d. | In early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID19) outbreak a pandemic. This pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Company considered the impact of COVID-19 on its operations and determined that there were no material adverse impacts on the Company’s results of operations and financial position as of June 30, 2022. These estimates may change, as new events occur and additional information is obtained. |
NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
| a. | Unaudited Interim Financial Statements |
The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Group’s Annual Report on Form 10-K for the year ended December 31, 2021.
| b. | Principles of Consolidation |
The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
| c. | Use of estimates |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.
| - 13 - |
SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued):
| d. | Significant Accounting Policies |
The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.
As described therein, to the extent development services are not distinct from the performance obligation relating to the subsequent production phase, revenue from these services is deferred until commencement of the production phase. Further to the inception of the production phase (refer to Note 5), the Company recognizes deferred development services over the expected term of production.
| e. | Recent Accounting Pronouncements |
Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Group’s condensed consolidated financial statements.
NOTE 3 – LEASES:
On
June 30, 2022, the Group’s ROU assets and lease liabilities for operating leases totaled $
Lease
expenses recorded in the interim consolidated statements of operations were $
ScoutCam
subleases part of the office space to a third party for approximately $
Supplemental cash flow information related to operating leases was as follows:
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES
| Six months ended 30, 2022 | ||||
| USD in thousands | ||||
| Cash payments for operating leases | ||||
| Total lease expenses | ||||
As
of June 30, 2022, the Company’s operating leases had a weighted average remaining lease term of
| Operating leases | ||||
| USD in thousands | ||||
| Remainder of 2022 | ||||
| 2023 | ||||
| 2024 | ||||
| Total future lease payments | ||||
| Less imputed interest | ( | ) | ||
| Total lease liability balance | ||||
| - 14 - |
SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – EQUITY:
Warrants:
As of June 30, 2022, the Company had the following outstanding warrants to purchase common stock:
SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK
| Warrant | Issuance Date | Expiration Date | Exercise Price Per Share ($) | Number of Shares of common stock Underlying Warrants | ||||||||
| Warrant March 2021 | ||||||||||||
In
addition, if ScoutCam achieves an aggregate amount of $
| - 15 - |
SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – EQUITY (continued):
Share-based compensation to employees, directors and service providers:
In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”). The Plan initially included a pool of shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional shares of common stock.
The Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.
Stock option activity
During the six months ended June 30, 2022, the Company granted options pursuant to the Plan.
SCHEDULE OF SHARE-BASED PAYMENT, STOCK OPTIONS, VALUATION ASSUMPTIONS
Six months ended June 30, 2022 | ||||
| Underlying value of ordinary shares ($) | ||||
| Exercise price ($) | ||||
| Expected volatility (%) | % | |||
| Term of the options (years) | ||||
| Risk-free interest rate | % | |||
The cost of the benefit embodied in the options granted during the six months ended June 30, 2022, based on their fair value as at the grant date, is estimated to be approximately $ thousands. These amounts will be recognized in statements of operations over the vesting period.
| - 16 - |
SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – EQUITY (continued):
SCHEDULE OF STOCK OPTIONS ACTIVITY
For the Six months ended June 30, 2022 | ||||||||
Amount of options | Weighted average exercise price | |||||||
| $ | ||||||||
| Outstanding at beginning of period | ||||||||
| Granted | ||||||||
| Cancelled | ( | ) | ||||||
| Outstanding at end of period | ||||||||
| Vested at end of period | ||||||||
Restricted stock unit (“RSU”) activity
During the six months ended June 30, 2022, the Company granted RSUs pursuant to the Plan.
Each RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.
The cost of the benefit embodied in the RSU granted during the six months ended June 30, 2022, based on their fair value as at the grant date, is estimated to be approximately $ thousands. These amounts will be recognized in statements of operations over the vesting period
SCHEDULE OF STOCK OPTIONS ACTIVITY
For the Six months ended June 30, 2022 | ||||||||
Amount of options | Weighted Average Grant Date Fair Value per Share | |||||||
| $ | ||||||||
| Outstanding at beginning of period | ||||||||
| Granted | ||||||||
| Vested | ||||||||
| Forfeited | ||||||||
| Unvested and Outstanding at end of period | ||||||||
| - 17 - |
SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – EQUITY (continued):
SCHEDULE OF TOTAL SHARE-BASED PAYMENT EXPENSES
Six months ended June 30, 2022 | ||||
| USD in thousands | ||||
| Cost of revenues | ||||
| Research and development | ||||
| Sales and marketing | ||||
| General and administrative | ||||
| Total expenses | ||||
NOTE 5 – REVENUES:
Contract fulfillment assets and Contract liabilities:
The Company’s contract fulfillment assets and contract liabilities as of June 30, 2022 and December 31, 2021 were as follows:
SCHEDULE OF CONTRACT LIABILITIES
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| USD in thousands | ||||||||
| Contract fulfillment assets | ||||||||
| Contract liabilities | ||||||||
Contract liabilities include advance payments, which are primarily related to advanced billings for development services.
In the current quarter the Company completed the development service stage of its miniature camera solution relating these deferred development
services and moved from the development stage to the production stage. As a result, the Company recognized $
Remaining Performance Obligations
Remaining
Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue
and amounts that will be recognized as revenue in future periods. As of June 30, 2022, the total RPO amounted to $
| - 18 - |
NOTE 6 – SCOUTCAM INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 - INVENTORY:
Composed as follows:
SCHEDULE OF INVENTORY
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| USD in thousands | ||||||||
| Raw materials and supplies | ||||||||
| Work in progress | ||||||||
| Finished goods | ||||||||
| Inventory Net | ||||||||
During
the period ended June 30, 2022,
Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company, by the weighted average number of ordinary shares as described below.
In computing the Company’s diluted loss per share, the numerator used in the basic loss per share computation is adjusted for the dilutive effect, if any, of the Company’s potential shares of common stock. The denominator for diluted loss per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period.
NOTE 8 – RELATED PARTIES
a. Balances with related parties:
SCHEDULE OF BALANCES WITH RELATED PARTIES
| June 30, 2022 | December 31, 2021 | |||||||
| USD in thousands | ||||||||
| Directors(*) | ||||||||
| Medigus | ||||||||
| (*) |
| b. | During six months ended June 30, 2022 the Company received development services from Smartec R&D Ltd., a company owned by the Company’s CTO. |
Total
compensation during the six months ended June 30, 2022 and June 30, 2021 was approximately $
NOTE 9 – SUBSEQUENT EVENTS
| On July 12, 2022, the Company and the Chief Executive Officer of the Company, mutually agreed that the CEO’s employment with the Company would terminate on October 18, 2022. |
| - 19 - |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our Annual Report for the fiscal year ended December 31, 2021 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
The Company’s primary business activity during last few months was enlarging its focus on R&D activities in the domain of I4.0 (including Predictive Maintenance, PdM, and Condition Based Monitoring, CBM, in sectors such as the aviation, energy and automotive). The main effect of this activity was an increase in the number of employees to enable the Company to manage the anticipated increased workload and solution development.
In addition, recently the Company completed the verification and validation (V&V) stage of its miniature camera solution with a Fortune 500 company and moved from R&D stage to production stage.
Comparison of the six months ended June 30, 2022 and 2021
The following table summarizes our results of operations for the six months period ended June 30, 2022 and 2021, together with the changes in those items in dollars and as a percentage:
| Six months ended June 30, | ||||||||||||
| 2022 | 2021 | % Change | ||||||||||
| Revenues | 372,000 | 298,000 | 25 | % | ||||||||
| Cost of Revenues | 849,000 | 610,000 | 39 | % | ||||||||
| Gross Loss | (477,000 | ) | (312,000 | ) | 53 | % | ||||||
| Research and development expenses | 1,975,000 | 643,000 | 207 | % | ||||||||
| Sales and marketing expense | 446,000 | 404,000 | 10 | % | ||||||||
| General and administrative expenses | 2,452,000 | 2,328,000 | 5 | % | ||||||||
| Operating Loss | (5,350,000 | ) | (3,687,000 | ) | 45 | % | ||||||
Revenues
As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.
For the six months ended June 30, 2022, we generated revenues of $372,000, an increase of $74,000, or 25% from the six months ended June 30, 2021.
The increase in revenues was primarily due to the increase in revenue from our miniature camera solution with the Fortune 500 company due to completion R&D stage and moving to production stage. Total revenues recorded from our miniature camera solution with the Fortune 500 company during the six months ended June 30, 2022, amounted to approximately $327,000. We did not record any revenue from our miniature camera solution with the Fortune 500 company during the six months ended June 30, 2021.
This increase in revenues was partly offset by the following:
| - | Total revenues recorded from A.M. Surgical during the six months ended June 30, 2021, amounted to approximately $200,000. We did not record any revenue from A.M. Surgical during the six months ended June 30, 2022. | |
| - | the decrease of $53,000 due to an overall decrease in the sales of the Company’s component products to occasional customers. |
Cost of Revenues
Cost of revenue is primarily comprised of cost of personnel including warehouse personnel costs, inventory write-downs, certain allocated facilities and expenses associated with logistics and quality control.
Cost of revenues for the six months ended June 30, 2022 was $849,000, an increase of $239,000, or 39%, compared to cost of revenues of $610,000 for the six months ended June 30, 2021. The increase was primarily due to an increase in materials as a result of an increase in revenues, an increase in payroll expenses due to stock-based compensation and due to the transition from the R&D stage to the production stage as described on “Overview” and increase in facility costs due to a lease for additional office space.
| - 20 - |
Gross Loss
Gross loss for the six months ended June 30, 2022 was $477,000, an increase of $165,000, or 53%, compared to gross loss of $312,000 for the six months ended June 30, 2021.
The increase was primarily due to increase in cost of revenues partially offset by an increase in revenue as described above.
Research and Development Expenses
Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation and other supplies. We expense research and development costs as incurred.
Research and development expenses for the six months ended June 30, 2022 were $1,975,000, an increase of $1,332,000, or 207%, compared to $643,000 for the six months ended June 30, 2021.
The increase was primarily due to an increase in payroll expenses (including stock-based compensation), materials and subcontractors, and because we have recently begun examining additional applications for our micro ScoutCam™ portfolio outside of the medical, defense and aerospace fields, including in sectors such as automotive, industrial non-destructing-testing industries, automotive and energy and increase in facility costs due to a lease for additional office space.
In addition, there was an increase in R&D payroll expenses in first half of 2022 due to the fact that during the first half of 2021 a part of our payroll expenses was capitalized to contract fulfillment asset and was not recognized as expenses in profit and loss.
We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.
Sales and Marketing Expenses
Sales and marketing expenses primarily consist of personnel costs, consulting services, promotional materials, demonstration equipment and certain allocated facility infrastructure costs.
Sales and marketing expenses for the six months ended June 30, 2022 were $446,000, an increase of $42,000, or 10%, compared to $404,000 for the six months ended June 30, 2021.
The increase was primarily due to an increase in payroll expenses (including stock-based compensation) due to the recruitment of a VP Business Development in Industry 4.0.
We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.
General and Administrative Expenses
General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs, as well as professional fees for legal, patent, consulting, investor, and public relations, accounting, auditing, tax services and insurance costs.
General and Administrative expenses for the six months ended June 30, 2022 were $2,452,000, an increase of $124,000, or 5%, compared to $2,328,000 for the six months ended June 30, 2021.
The increase was primarily due to an increase in share based compensation due to new options and RSUs grants, partially offset by a decrease in IP expenses.
| - 21 - |
Operating loss
We incurred an operating loss of $5,350,000 for the six months ended June 30, 2022, an increase of $1,663,000, or 45%, compared to operating loss of $3,687,000 for the six months ended June 30, 2021.
The increase in operating loss was primarily due to increases in expenses related to general and administrative, research and development and sales and marketing, as described above.
Cash Flows
The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):
| Six month ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash used in Operating Activity | (2,398,000 | ) | (3,054,000 | ) | ||||
| Cash provided by (used in) Investing Activity | 1,458,000 | (170,000 | ) | |||||
| Cash provided by Financing Activity | - | 21,622,000 | ||||||
Operating Activities
Our primary uses of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost and costs related to our facilities. Our cash flows from operating activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.
During the six months ended June 30, 2022, cash used in operating activities was $2.4 million, consisting of net loss of $5.6 million, partially offset by a non-cash benefit of $1.5 million, a favorable net change in operating assets and liabilities of $1.3 million and loss from exchange differences on cash and cash equivalents of $0.3 million. Our non-cash benefit consisted primarily of non-cash charges of $1.5 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in contract liability of $1.4 million.
During the six months ended June 30, 2021, cash used in operating activities was $3.1 million, consisting of net loss of $3.7 million partially offset by a non-cash benefit of $0.6 million. Our non-cash benefit consisted primarily of non-cash charges of $0.6 million for stock-based compensation.
| - 22 - |
Investing Activities
For the six months ended June 30, 2022, net cash flows provided by investing activities was $1,458,000, due to change of $1,500,000 in short terms deposits partially offset by the purchase of property and equipment.
For the six months ended June 30, 2021, net cash flows used in investing activities was $170,000, due to the purchase of property and equipment.
Financing Activities
For the six months ended June 30, 2021, net cash flows provided by financing activities was $21.6 million, due to proceeds from the issuance of shares and warrants equivalent to approximately $19.1 million and proceeds from exercise from warrants of approximately $2.5 million.
Comparison of the three months ended June 30, 2022 and 2021
The following table summarizes our results of operations for the three months period ended June 30, 2022, and 2021, together with the changes in those items in dollars and as a percentage:
| Three months ended June 30, | ||||||||||||
| 2022 | 2021 | % Change | ||||||||||
| Revenues | 370,000 | 274,000 | 35 | % | ||||||||
| Cost of Revenues | 561,000 | 407,000 | 38 | % | ||||||||
| Gross Loss | (191,000 | ) | (133,000 | ) | 44 | % | ||||||
| Research and development expenses | 1,021,000 | 362,000 | 182 | % | ||||||||
| Sales and marketing expense | 203,000 | 207,000 | (2) | % | ||||||||
| General and administrative expenses | 1,166,000 | 1,395,000 | (16) | % | ||||||||
| Operating Loss | (2,581,000 | ) | (2,097,000 | ) | 23 | % | ||||||
Revenues
For the three months ended June 30, 2022, we generated revenues of $370,000, an increase of $96,000, or 35%, from the three months ended June 30, 2021.
The increase in revenues was primarily due to the increase in revenue from our miniature camera solution with the Fortune 500 company due to completion R&D stage and moving to production stage. Total revenues recorded from our miniature camera solution with the Fortune 500 company during the six months ended June 30, 2022, amounted to approximately $327,000. We did not record any revenue from our miniature camera solution with the Fortune 500 company during the three months ended June 30, 2021.
This increase in revenues was partly offset by the following:
| - | Total revenues recorded from A.M. Surgical during the six months ended June 30, 2021, amounted to approximately $200,000. We did not record any revenue from A.M. Surgical during the three months ended June 30, 2022. | |
| - | the decrease of $31,000 due to an overall decrease in the sales of the Company’s component products to occasional customers. |
Cost of Revenues
Cost of revenue is primarily comprised of cost of personnel including warehouse personnel costs, inventory write-downs, certain allocated facilities and expenses associated with logistics and quality control.
Cost of revenues for the three months ended June 30, 2022 was $561,000, an increase of $154,000, or 38%, compared to cost of revenues of $407,000 for the three months ended June 30, 2021.
| - 23 - |
The increase was primarily due to an increase in materials as a result of an increase in revenues, an increase in payroll expenses due to stock-based compensation and due to the transition from the R&D stage to the production stage as described on “Overview” and increase in facility costs due to a lease for additional office space.
Gross Loss
Gross loss for the three months ended June 30, 2022 was $191,000, an increase of $58,000, or 44%, compared to gross loss of $133,000 for the three months ended June 30, 2021.
The increase was primarily due to increase in cost of revenues partially offset by an increase in revenue as described above.
Research and Development Expenses
Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation and other supplies. We expense research and development costs as incurred.
Research and development expenses for the three months ended June 30, 2022 were $1,021,000, an increase of $659,000, or 182%, compared to $362,000 for the three months ended June 30, 2021.
The increase was primarily due to an increase in payroll expenses (including stock-based compensation), materials and subcontractors, and because we have recently begun examining additional applications for our micro ScoutCam™ portfolio outside of the medical, defense and aerospace fields, including in sectors such as automotive, industrial non-destructing-testing industries, automotive and energy and increase in facility costs due to a lease for additional office space.
We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.
Sales and Marketing Expenses
Sales and marketing expenses primarily consist of personnel costs, consulting services, promotional materials, demonstration equipment and certain allocated facility infrastructure costs.
Sales and marketing expenses for the three months ended June 30, 2022 were $203,000, a decrease of $4,000, or 2%, compared to $207,000 for the three months ended June 30, 2021.
We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.
General and Administrative Expenses
General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs, as well as professional fees for legal, patent, consulting, investor, and public relations, accounting, auditing, tax services and insurance costs.
General and Administrative expenses for the three months ended June 30, 2022 were $1,166,000, a decrease of $229,000, or 16%, compared to $1,395,000 for the three months ended June 30, 2021.
The decrease was primarily due to a decrease in IP expenses.
Operating loss
We incurred an operating loss of $2,581,000 for the three months ended June 30, 2022, an increase of $484,000, or 23%, compared to operating loss of $2,097,000 for the three months ended June 30, 2021.
The increase in operating loss was primarily due to increases in expenses related to general and administrative, research and development and sales and marketing, as described above.
| - 24 - |
Cash Flows
The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):
| Three month ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash used in Operating Activity | (2,174,000 | ) | (2,280,000 | ) | ||||
| Cash provided by (used in) Investing Activity | 1,482,000 | (53,000 | ) | |||||
| Cash provided by Financing Activity | - | 11,341,000 | ||||||
Operating Activities
Our primary use of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost and costs related to our facilities. Our cash flows from operating activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.
During the three months ended June 30, 2022, cash used in operating activities was $2.2 million, consisting of net loss of $2.8 million and an unfavorable net change in operating assets and liabilities of $0.4 million partially offset by a non-cash benefit of $0.7 million, and loss from exchange differences on cash and cash equivalents of $0.3 million. Our non-cash benefit consisted primarily of non-cash charges of $0.7 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in inventory of $0.4 million.
Investing Activities
For the three months ended June 30, 2022, net cash flows provided by investing activities was $1,482,000, due to change of $1,500,000 in short terms deposits partially offset by the purchase of property and equipment.
For the three months ended June 30, 2021, net cash flows used in investing activities was $53,000, due to the purchase of property and equipment.
Financing Activities
For the three months ended June 30, 2021, net cash flows provided by financing activities was $11.3 million, due to proceeds from the issuance of shares and warrants equivalent to approximately $9.6 million and proceeds from exercise from warrants of approximately $1.7 million.
Additional Cash Requirements
We plan to continue to invest for long-term growth, and therefore we expect that our expenses will increase. We currently believe that our existing cash and cash equivalents and short-term deposits will be sufficient to meet our anticipated cash needs for at least the next 12 months. We expect our expenses will increase in connection with our ongoing activities, particularly as we continue the research and development and the scale up process of our I4.0 solutions. We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We may raise these funds through equity financing, debt financing or other sources, which may result in further dilution in the equity ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.
Liquidity and Capital Resources
As of June 30, 2022, we had cash and cash equivalents of $7.3 million and $9.5 million of short-term deposits compared to cash and cash equivalents $8.6 million and $11 million of short-term deposits as of December 31, 2021. In addition, as of June 30, 2022 we incurred an accumulated deficit of approximately $20.9 million, compared to $15.3 million as of December 31, 2021.
Our primary sources of liquidity to date have been from fund raising and warrant exercises.
| - 25 - |
Off-Balance Sheet Arrangements
None.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
As a smaller reporting company, we are not required to provide the information requested by this Item.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Exchange Act Rule 13a-15(e). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.
No change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(e), occurred during the fiscal quarter ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| - 26 - |
PART II- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.
ITEM 1A. RISK FACTORS.
There have been no material changes from the information set forth in “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31,2021 as filed with the SEC on March 30, 2022.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
There have been no unregistered sales of equity securities in addition to the sales provided under Form 8-K as filed with the SEC during the recent fiscal quarter ended June 30, 2022.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURE
Not applicable.
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS.
(a) The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.
| - 27 - |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 11, 2022 | SCOUTCAM INC. | |
| By: | /s/ Benad Goldwasser | |
| Name: | Benad Goldwasser | |
| Title: | Chairman of the Board | |
| ScoutCam Inc. | ||
| By: | /s/ Tanya Yosef | |
| Name: | Tanya Yosef | |
| Title: | Chief Financial Officer | |
| ScoutCam Inc. | ||
| - 28 - |
Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Benad Goldwasser, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022 of ScoutCam Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the quarter end covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the quarter end presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the quarter end in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the quarter end covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: August 11, 2022 | |
| /s/ Benad Goldwasser | |
| Benad Goldwasser | |
| Chairman of the Board | |
| Principal Executive Officer |
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Tanya Yosef, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022, of ScoutCam Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the quarter end covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the quarter end presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the quarter end in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the quarter end covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: August 11, 2022 | |
| /s/ Tanya Yosef | |
| Tanya Yosef | |
| Chief Financial Officer |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of ScoutCam Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Benad Goldwasser, Chairman of the Board and principal executive officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Benad Goldwasser | |
| Benad Goldwasser | |
| Chairman of the Board | |
| Principal Executive Officer | |
| ScoutCam Inc. | |
| August 11, 2022 |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of ScoutCam Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Tanya Yosef, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Tanya Yosef | |
| Tanya Yosef | |
| Chief Financial Officer | |
| ScoutCam Inc. | |
| August 11, 2022 |